Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split, Massachusetts, Lexington Beloud

@wfmz.com · 1 hour

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Curis, Inc. has announced that eleven clinical sites are now open for patient enrollment in its Phase 2 TakeAim CLL study, which evaluates emavusertib in combination with zanubrutinib. The c...

Read more Wfmz.com